Pharma Mar SA (PHMMF)
94.60
0.00 (0.00%)
USD |
OTCM |
Sep 24, 16:00
Pharma Mar Cash from Operations (TTM) : 72.48M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 72.48M |
| March 31, 2026 | 78.50M |
| December 31, 2025 | 61.84M |
| September 30, 2025 | 24.51M |
| June 30, 2025 | 9.575M |
| March 31, 2025 | -10.20M |
| December 31, 2024 | 6.509M |
| September 30, 2024 | 1.954M |
| June 30, 2024 | -10.30M |
| March 31, 2024 | -12.84M |
| December 31, 2023 | -14.71M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | 53.21M |
| March 31, 2022 | 52.58M |
| December 31, 2021 | 29.69M |
| September 30, 2021 | 41.55M |
| June 30, 2021 | 28.70M |
| March 31, 2021 | 131.29M |
| December 31, 2020 | 308.23M |
| September 30, 2020 | 296.05M |
| June 30, 2020 | 283.59M |
| Date | Value |
|---|---|
| March 31, 2020 | 181.53M |
| December 31, 2019 | -29.42M |
| September 30, 2019 | -26.05M |
| June 30, 2019 | -11.31M |
| March 31, 2019 | -25.16M |
| December 31, 2018 | -19.20M |
| September 30, 2018 | -22.68M |
| June 30, 2018 | -27.46M |
| March 31, 2018 | -22.64M |
| December 31, 2017 | -2.075M |
| September 30, 2017 | 3.355M |
| June 30, 2017 | 9.000M |
| March 31, 2017 | 13.34M |
| December 31, 2016 | -9.510M |
| September 30, 2016 | 3.731M |
| June 30, 2016 | 5.192M |
| March 31, 2016 | -1.538M |
| December 31, 2015 | 12.10M |
| September 30, 2015 | 7.932M |
| June 30, 2015 | 11.21M |
| March 31, 2015 | 18.00M |
| December 31, 2014 | 28.56M |
| September 30, 2014 | 33.77M |
| June 30, 2014 | 32.44M |
| March 31, 2014 | 24.77M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Oryzon Genomics SA | -- |
| Grifols SA | 1.264B |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alkermes Plc | 251.18M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |